IDYA
Price
$21.67
Change
-$0.19 (-0.87%)
Updated
Jun 20 closing price
Capitalization
1.9B
51 days until earnings call
REPL
Price
$9.27
Change
-$0.22 (-2.32%)
Updated
Jun 20 closing price
Capitalization
714.59M
38 days until earnings call
Interact to see
Advertisement

IDYA vs REPL

Header iconIDYA vs REPL Comparison
Open Charts IDYA vs REPLBanner chart's image
IDEAYA Biosciences
Price$21.67
Change-$0.19 (-0.87%)
Volume$780.09K
Capitalization1.9B
Replimune Group
Price$9.27
Change-$0.22 (-2.32%)
Volume$1.47M
Capitalization714.59M
IDYA vs REPL Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. REPL commentary
Jun 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and REPL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 23, 2025
Stock price -- (IDYA: $21.67 vs. REPL: $9.27)
Brand notoriety: IDYA and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 60% vs. REPL: 118%
Market capitalization -- IDYA: $1.9B vs. REPL: $714.59M
IDYA [@Biotechnology] is valued at $1.9B. REPL’s [@Biotechnology] market capitalization is $714.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $326.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • REPL’s FA Score: 1 green, 4 red.
According to our system of comparison, REPL is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 5 TA indicator(s) are bullish while REPL’s TA Score has 5 bullish TA indicator(s).

  • IDYA’s TA Score: 5 bullish, 5 bearish.
  • REPL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, REPL is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а -2.30% price change this week, while REPL (@Biotechnology) price change was -5.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.57%. For the same industry, the average monthly price growth was +27.78%, and the average quarterly price growth was +14.34%.

Reported Earning Dates

IDYA is expected to report earnings on Aug 12, 2025.

REPL is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+9.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($1.9B) has a higher market cap than REPL($715M). IDYA YTD gains are higher at: -15.681 vs. REPL (-23.452). REPL has higher annual earnings (EBITDA): -235.43M vs. IDYA (-356.46M). IDYA has more cash in the bank: 693M vs. REPL (484M). IDYA has less debt than REPL: IDYA (26M) vs REPL (76.2M). IDYA has higher revenues than REPL: IDYA (7M) vs REPL (0).
IDYAREPLIDYA / REPL
Capitalization1.9B715M265%
EBITDA-356.46M-235.43M151%
Gain YTD-15.681-23.45267%
P/E RatioN/AN/A-
Revenue7M0-
Total Cash693M484M143%
Total Debt26M76.2M34%
FUNDAMENTALS RATINGS
IDYA vs REPL: Fundamental Ratings
IDYA
REPL
OUTLOOK RATING
1..100
8150
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
27
Undervalued
PROFIT vs RISK RATING
1..100
64100
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
5358
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (27) in the Biotechnology industry is somewhat better than the same rating for IDYA (63) in the null industry. This means that REPL’s stock grew somewhat faster than IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (64) in the null industry is somewhat better than the same rating for REPL (100) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than REPL’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as REPL (98) in the Biotechnology industry. This means that IDYA’s stock grew similarly to REPL’s over the last 12 months.

IDYA's Price Growth Rating (53) in the null industry is in the same range as REPL (58) in the Biotechnology industry. This means that IDYA’s stock grew similarly to REPL’s over the last 12 months.

IDYA's P/E Growth Rating (100) in the null industry is in the same range as REPL (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAREPL
RSI
ODDS (%)
Bearish Trend 3 days ago
69%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
77%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
Bullish Trend 20 days ago
76%
Bullish Trend 17 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 3 days ago
78%
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RUSRX10.51N/A
N/A
Lazard US Systematic Small Cap Eq R6
PCVCX8.99-0.01
-0.11%
Virtus NFJ Small-Cap Value C
PABAX16.28-0.03
-0.18%
Putnam Dynamic Asset Allocation Bal A
JMGMX53.47-0.11
-0.21%
JPMorgan Mid Cap Growth R6
GTTTX30.40-0.10
-0.33%
Goldman Sachs Small Cp Val Insghts Inv

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-0.87%
IMNM - IDYA
60%
Loosely correlated
-0.91%
CGON - IDYA
60%
Loosely correlated
-2.78%
CRNX - IDYA
56%
Loosely correlated
N/A
XENE - IDYA
56%
Loosely correlated
+0.47%
COGT - IDYA
55%
Loosely correlated
-0.14%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with ELVAF. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
-2.32%
ELVAF - REPL
60%
Loosely correlated
N/A
SNDX - REPL
51%
Loosely correlated
-2.17%
IDYA - REPL
51%
Loosely correlated
-0.87%
XNCR - REPL
50%
Loosely correlated
+2.15%
CGON - REPL
46%
Loosely correlated
-2.78%
More